1Gene Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

Hangzhou Zhejiang China

Primary Industry

Biotechnology

About

Established in 2014 and based in Hangzhou, China, 1Gene operates as a genetic testing institute that provides cancer early screening products and has partnerships with aliyun.com, Zhejiang Cancer Hospital, Illumina, etc. It qualified as a medical laboratory in January 2017. In April 2022, it passed the KRAS mutation interval quality assessment with a full score. The company's products can be categorized into bowel cancer early screening, stomach cancer early screening, gastrointestinal cancer early screening, fecal occult blood self-test, full set of tumor genetic susceptibility tests, and gastric cancer pathogenic bacteria screening and medication guidance.

Current Investors

TiSiWi, Everfine Corporation, Chengda Pharmaceuticals Co., Ltd.

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories

Website

www.1gene.com.cn

Verticals

Big Data

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.